Risk factors and incidence of de novo malignancy in liver transplant recipients: A systematic review

Liver International

Volumn 30, Issue 9, 2010, Pages 1247-1258

  Chak, Eric ^a   Saab, Sammy ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

De novo malignancy; Liver transplantation

Indexed keywords

ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; CIGARETTE SMOKING; COLON CANCER; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; DISEASE SURVEILLANCE; ENTERITIS; GRAFT RECIPIENT; GROUPS BY AGE; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER TRANSPLANTATION; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; PRIMARY SCLEROSING CHOLANGITIS; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SAFETY; SUN EXPOSURE; SYSTEMATIC REVIEW; UROGENITAL TRACT CANCER;

COMORBIDITY; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; INCIDENCE; LIVER CIRRHOSIS, ALCOHOLIC; LIVER TRANSPLANTATION; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; SUNLIGHT;

EID: 78349266826     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02303.x     Document Type: Review

References (92)

1. National Institutes of Health Consensus Development Conference Statement: liver transplantation - June 20-23, 1983. Hepatology 1984; 4 (Suppl.): 107S-10.
2. Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant 2006; 20: 617-23.
3. Pruthi J, Medkiff KA, Esrason KT, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811-5.
4. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004; 10: 534-40.
5. Jain A, Reyes J, Kashyap R, et al. Long-term survival after liver transplantation in 4, 000 consecutive patients at a single center. Ann Surg 2000; 232: 490-500.
6. Jain AB, Yee LD, Nalesnik MA, et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998; 66: 1193-200.
7. Haagsma EB, Hagens VE, Schaapveld M, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001; 34: 84-91.
8. Penn I. Depressed immunity and the development of cancer. Clin Exp Immunol 1981; 46: 459-74.
9. Lotzova E. Definition and functions of natural killer cells. Nat Immunol 1993; 12: 169-76.
10. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-4.
11. Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann.Surg 1968; 168: 416-35.
12. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncog 1989; 1: 27-52.
13. Benlloch S, Berenguer M, Prieto M, et al. De novo internal neoplasms after liver transplantation: increased risk and aggressive behavior in recent years? Am J Transplant 2004; 4: 596-604.
14. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623-8.
15. Kenngott S, Gerbes AL, Schauer R, Bilzer M. Rapid development of esophageal squamous cell carcinoma after liver transplantation for alcohol-induced cirrhosis. Transpl Int 2003; 16: 639-41.
16. Yao F, Ahuja J, Savides T, et al. Rapid progression of gastroesophageal junction adenocarcinoma after liver transplantation. J Clin Gastroenterol 1997; 24: 54-5.
17. Saigal S, Norris S, Muiesan P, et al. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation. Liver Transpl 2002; 8: 482-7.
18. Van Der Heide F, Dijkstra G, Porte RJ, Kleibeuker JH, Haagsma EB. Smoking behavior in liver transplant recipients. Liver Transpl 2009; 15: 648-55.
19. Lee DS, Mathur AK, Acker WB II, et al. Effects of smoking on survival for patients with end-stage liver disease. J Am Coll Surg 2009; 208: 1077-84.
20. Leithead JA, Ferguson JW, Hayes PC. Smoking-related morbidity and mortality following liver transplantation. Liver Transpl 2008; 14: 1159-64.
21. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-50.
22. Jain A, Reyes J, Kashyap R, et al. Liver transplantation under tacrolimus in infants, children, adults, and seniors: long-term results, survival, and adverse events in 1000 consecutive patients. Transplant Proc 1998; 30: 1403-4.
23. Jimenez C, Rodriguez D, Marques E, et al. De novo tumors after orthotopic liver transplantation. Transplant Proc 2002; 34: 297-8.
24. Jimenez C, Marques E, Loinaz C, et al. Upper aerodigestive tract and lung tumors after liver transplantation. Transplant Proc 2003; 35: 1900-1.
25. Watson RR. Ethanol, immunomodulation and cancer. Prog Food Nutr Sci 1988; 12: 189-209.
26. Ben-Eliyahu S, Page GG, Yirmiya R, Taylor AN. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 1996; 2: 457-60.
27. Surveillance Epidemiology and End Results. 2002-2006; Available at (accessed 10 October 2009).
28. Jimenez C, Marques E, Manrique A, et al. Incidence and risk factors of development of lung tumors after liver transplantation. Transplant Proc 2005; 37: 3970-2.
29. Caygill CP, Reed PI, Johnston BJ, et al. A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Hepatol 1999; 11: 1355-8.
30. Ilan Y, Shouval D, Galun E, et al. Esophageal malignancy after liver transplantation in a patient with Barrett's esophagus. Scand J Gastroenterol 1996; 31: 415-6.
31. Menachem Y, Safadi R, Ashur Y, Ilan Y. Malignancy after liver transplantation in patients with premalignant conditions. J Clin Gastroenterol 2003; 36: 436-9.
32. Saigal S, Norris S, Srinivasan P, et al. Successful outcome of orthotopic liver transplantation in patients with preexisting malignant states. Liver Transpl 2001; 7: 11-5.
33. Dousset B, Boudet MJ, Soubrane O, et al. Liver transplantation in patients with preexisting malignancy. Transplant Proc 1995; 27: 1793-5.
34. Benten D, Sterneck M, Panse J, Rogiers X, Lohse AW. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Liver Transpl 2008; 14: 789-98.
35. Gupta AK, Gupta A, Bhardwaj VK, Chansoria M. Caroli's disease. Indian J Pediatr 2006; 73: 233-5.
36. Kelly DM, Emre S, Guy SR, et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998; 83: 1237-43.
37. Xiol X, Guardiola J, Menendez S, et al. Risk factors for development of de novo neoplasia after liver transplantation. Liver Transpl 2001; 7: 971-5.
38. Mithoefer AB, Supran S, Freeman RB. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 2002; 8: 939-44.
39. Jimenez-Romero C, Manrique Municio A, Marques Medina E, et al. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases. Transplant Proc 2006; 38: 2505-7.
40. Aseni P, Vertemati M, De Carlis L, et al. De novo cancers and post-transplant lymphoproliferative disorder in adult liver transplantation. Pathol Int 2006; 56: 712-5.
41. Sanchez EQ, Marubashi S, Jung G, et al. De novo tumors after liver transplantation: a single-institution experience. Liver Transpl 2002; 8: 285-91.
42. Euvrard S, Kanitakis J. Skin cancers after liver transplantation: what to do? J Hepatol 2006; 44: 27-32.
43. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transpl 2005; 11: 1100-6.
44. Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 1993; 25 (Part 2): 1397-9.
45. Baccarani U, Adani GL, Serraino D, et al. De novo tumors are a major cause of late mortality after orthotopic liver transplantation. Transplant Proc 2009; 41: 1303-5.
46. Caforio AL, Fortina AB, Piaserico S, et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000; 102 (Suppl. 3): 222-7.
47. Espana A, Martinez-Gonzalez MA, Garcia-Granero M, et al. A prospective study of incident nonmelanoma skin cancer in heart transplant recipients. J Invest Dermatol 2000; 115: 1158-60.
48. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40: 27-34.
49. McGregor JM, Harwood CA, Brooks L, et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J Invest Dermatol 2002; 119: 84-90.
50. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003; 348: 1681-9.
51. Bismuth H, Samuel D, Venancie PY, Menouar G, Szekely AM. Development of Kaposi's sarcoma in liver transplant recipients: characteristics, management, and outcome. Transplant Proc 1991; 23 (Part 2): 1438-9.
52. Penn I. Posttransplant malignancies. Transplant Proc 1999; 31: 1260-2.
53. Cattani P, Capuano M, Graffeo R, et al. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients. J Clin Microbiol 2001; 39: 506-8.
54. Euvrard S, Kanitakis J, Bosshard S, et al. No recurrence of posttransplantation Kaposi's sarcoma three years after renal retransplantation. Transplantation 2002; 73: 297-9.
55. Frezza EE, Fung JJ, Van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-81.
56. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-92.
57. Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol 2006; 44: 19-23.
58. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002; 6: 280-7.
59. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-53.
60. Duvoux C, Pageaux GP, Vanlemmens C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 1103-9.
61. McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000; 6: 570-4.
62. Ferri C, Giuggioli D, Cazzato M, et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 2003; 21 (Suppl. 32): S78-84.
63. Nicolaasa JS, De Jongea V, Steyerbergb EW, et al. Risk of colorectal carcinoma in post-liver transplant patients: A Systematic Review and Meta-analysis. Am J Transplant 2010; 10: 868-76.
64. Albright JB, Bonatti H, Stauffer J, et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis 2009; 12 (Suppl. 32): 657-66.
65. Buell JF, Papaconstantinou HT, Skalow B, et al. De novo colorectal cancer: five-year survival is markedly lower in transplant recipients compared with the general population. Transplant Proc 2005; 37: 960-1.
66. Johnson EE, Leverson GE, Pirsch JD, Heise CP. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg 2007; 11: 272-9.
67. Finkenstedt A, Graziadei IW, Oberaigner W, et al. Extensive surveillance promotes early diagnosis and improved survival of de novo malignancies in liver transplant recipients. Am J Transplant 2009; 9: 2355-61.
68. Vera A, Gunson BK, Ussatoff V, et al. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003; 75: 1983-8.
69. Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis Colon Rectum 1993; 36: 908-12.
70. Papatheodoridis GV, Hamilton M, Mistry PK, et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998; 43: 639-44.
71. Fabia R, Levy MF, Testa G, et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998; 176: 265-9.
72. Tallon Aguilar L, Barrera Pulido L, Bernal Bellido C, et al. Causes and predisposing factors of de novo tumors in our series of liver transplant recipients. Transplant Proc 2009; 41: 2453-4.
73. Duvoux C, Delacroix I, Richardet JP, et al. Increased incidence of oropharyngeal squamous cell carcinomas after liver transplantation for alcoholic cirrhosis. Transplantation 1999; 67: 418-21.
74. Jain A, DiMartini A, Kashyap R, et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70: 1335-42.
75. Bellamy CO, DiMartini AM, Ruppert K, et al. Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 2001; 72: 619-26.
76. Schmilovitz-Weiss H, Mor E, Sulkes J, et al. De novo tumors after liver transplantation: a single-center experience. Transplant Proc 2003; 35: 665-6.
77. Castelli E, Hrelia P, Maffei F, et al. Indicators of genetic damage in alcoholics: reversibility after alcohol abstinence. Hepatogastroenterology 1999; 46: 1664-8.
78. Franceschi S, Talamini R, Barra S, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990; 50: 6502-7.
79. Jimenez C, Manrique A, Marques E, et al. Incidence and risk factors for the development of lung tumors after liver transplantation. Transpl Int 2007; 20: 57-63.
80. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion no. 452: Primary and preventive care: periodic assessments. Obstet Gynecol 2009; 114: 1444-51.
81. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-91.
82. Herrero JI, Alegre F, Quiroga J, et al. Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. Clin Transplant 2009; 23: 532-6.
83. Schumacher G, Oidtmann M, Rosewicz S, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34: 1392-3.
84. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128-35.
85. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-11.
86. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002; 360: 436-42.
87. Snydman DR, Falagas ME. Prevention of cytomegalovirus disease in transplant recipients. Lancet 1996; 347: 268-9.
88. Torres-Madriz G, Boucher HW. Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients. Clin Infect Dis 2008; 47: 702-11.
89. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med 2009; 169: 2078-86.
90. Hall EJ. Lessons we have learned from our children: cancer risks from diagnostic radiology. Pediatr Radiol 2002; 32: 700-6.
91. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected. Am J Gastroenterol 2009; 104: 739-50.
92. Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006; 6 (Part 1): 1017-24.